What is the recommended frequency for administering intravenous immunoglobulin (IVIG) as maintenance therapy in patients with myasthenia gravis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

IVIG Maintenance Frequency for MOGAD

I cannot provide a definitive recommendation for IVIG maintenance frequency in MOGAD (Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease) because none of the provided evidence addresses MOGAD specifically—all references discuss other conditions (Rasmussen syndrome, cardiac transplant rejection, rheumatic diseases, myasthenia gravis, pemphigus, ITP, and primary immunodeficiency).

Critical Issue: Wrong Disease Context

The evidence provided is entirely irrelevant to your question about MOGAD. The expanded question incorrectly substitutes "myasthenia gravis" for MOGAD, which are completely different neuroinflammatory conditions with distinct pathophysiology and treatment paradigms.

What the Evidence Actually Shows (For Other Conditions)

While I cannot answer your MOGAD question, the evidence does reveal IVIG dosing patterns for other autoimmune conditions:

For Myasthenia Gravis (NOT MOGAD):

  • Maintenance dosing: 400 mg/kg monthly or 1 g/kg every 3-4 weeks 1, 2
  • Initial loading: 400 mg/kg/day for 5 days, then monthly maintenance 1
  • Some protocols use 1-2 g/kg monthly 3, 4

For Rasmussen Syndrome:

  • Maintenance: 1 g/kg every 4 weeks 5

For Primary Immunodeficiency:

  • 300-600 mg/kg every 3-4 weeks 6

What You Need Instead

For MOGAD-specific guidance, you would need:

  • MOGAD treatment guidelines or consensus statements
  • Studies specifically examining IVIG in MOGAD patients
  • Evidence comparing IVIG to other MOGAD maintenance therapies (rituximab, azathioprine, mycophenolate)

The dosing frequency for MOGAD may differ substantially from myasthenia gravis due to different disease mechanisms, relapse patterns, and treatment goals.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.